美股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

Silexion Therapeutics Corp

1.11

-0.1400-11.20%

盤前：1.140.0300+2.70%08:09 EDT

成交量：59.72萬

成交額：70.29萬

市值：934.02萬

市盈率：-0.91

高：1.26

開：1.23

低：1.11

收：1.25

資料載入中...

總覽公司新聞公告

公司資料

公司名字：

Silexion Therapeutics Corp

交易所：

NASDAQ

成立時間：

2008

員工人數：

- -

公司地址：

The Goldyne Savad Institute of Gene Therapy,Hadassah Hebrew University Medical Center,Jerusalem,Israel

官網：

http://www.silexion.com

郵編：

9112001

電話：

傳真：

972 2 643 0982

簡介：

Silexion Therapeutics Corp是一家開曼群島豁免公司。Silexion Therapeutics Ltd.是Biomotion Sciences的子公司。Silexion Therapeutics Ltd.是一家臨床階段、專註於腫瘤學的生物技術公司，致力於發現和開發KRAS驅動的癌症的專有療法。Silexion的主要候選產品SIL-204B由局部給藥的小干擾RNA或siRNA組成，採用緩釋製劑，作為局部晚期胰腺癌患者的一線治療，與標準護理化療相結合。SIL-204B是繼Silexion的第一代siRNA候選產品SIG12D-LODER（也稱為Loder）的1期和2期臨床試驗之後的第二代siRNA候選產品。儘管未確定最大耐受劑量，但1期臨床試驗同時達到了主要和次要終點。在2期臨床試驗中，雖然沒有達到所有患者的主要終點，但結果显示KRAS G12D/V突變患者的治療組之間存在差異趨勢，Loder組的總體生存期優勢為9.3個月。關於2期臨床試驗中的次要安全性終點，達到了終點。對於次要療效終點，未觀察到統計學上的顯著差異，也沒有足夠的數據進行評估。由於1期和2期試驗的規模較小，它們沒有提供統計學意義。

董事

名稱

職位

Ilan Levin

Chairman of the Board, Director, Secretary and Chief Executive Officer

Craig Marshak

Director

Eric Brachfeld

Director

Michael Basch

Director

Ruth Alon

Director

股東

名稱

職位

Ilan Levin

Chairman of the Board, Director, Secretary and Chief Executive Officer

Gil Maman

Chief Financial Officer

Dan Yalon

Advisor

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/SLXN/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SLXN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLXN\",,,,,undefined,":{"symbol":"SLXN","market":"US","secType":"STK","nameCN":"Silexion Therapeutics Corp","latestPrice":1.11,"timestamp":1742414400000,"preClose":1.25,"halted":0,"volume":597177,"hourTrading":{"tag":"盘前","latestPrice":1.14,"preClose":1.11,"latestTime":"08:09 EDT","volume":352,"amount":401.036416,"timestamp":1742472555441},"delay":0,"changeRate":-0.112,"change":-0.14,"floatShares":5231700,"shares":8414615,"eps":-1.215216,"lyrEps":0.386244,"amount":702857.2041350999,"amplitude":0.11848,"volumeRatio":0.28087234137056494,"dividePrice":0,"prevYearClose":2.01,"fiveDayClose":1.38,"twentyDayClose":0.9877},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLXN\",,,,,undefined,":{"symbol":"SLXN","floatShares":5231700,"roa":"--","roe":"--","lyrEps":0.386244,"volumeRatio":0.28087234137056494,"shares":8414615,"dividePrice":0,"high":1.2581,"amplitude":0.11848,"preClose":1.25,"low":1.11,"week52Low":0.575,"pbRate":"--","week52High":122.0184,"institutionHeld":0,"latestPrice":1.11,"committee":0.695775,"eps":-1.215216,"divideRate":0,"volume":597177,"delay":0,"ttmEps":-1.215216,"open":1.23,"prevYearClose":2.01,"prevWeekClose":1.31,"prevMonthClose":1.07,"prevQuarterClose":2.01,"fiveDayClose":1.38,"twentyDayClose":0.9877,"sixtyDayClose":2.14},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SLXN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-11-29","symbol":"SLXN","defaultRemindTime":1732890600000,"type":"split","dateTimestamp":1732856400000,"forFactor":9,"toFactor":1,"ratio":9},{"market":"US","date":"2024-08-13","symbol":"SLXN","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1723521600000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SLXN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SLXN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1730520000000},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":134350646,"yearFounded":2008,"address":"The Goldyne Savad Institute of Gene Therapy,Hadassah Hebrew University Medical Center,Jerusalem,Israel","zipCode":"9112001","officePhone":"972 2 674 3430","officeFax":"972 2 643 0982"},"stockCompanyDetail":{"websiteUrl":"http://www.silexion.com","stockEarnings":[{"period":"1week","weight":-0.1957},{"period":"1month","weight":0.0278},{"period":"3month","weight":-0.5413},{"period":"6month","weight":-0.8582},{"period":"1year","weight":-0.9889},{"period":"ytd","weight":-0.4478}],"compareEarnings":[{"period":"1week","weight":0.0148},{"period":"1month","weight":-0.0698},{"period":"3month","weight":-0.0324},{"period":"6month","weight":-0.002},{"period":"1year","weight":0.0997},{"period":"ytd","weight":-0.0323}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"Silexion Therapeutics Corp是一家開曼群島豁免公司。Silexion Therapeutics Ltd.是Biomotion Sciences的子公司。Silexion Therapeutics Ltd.是一家臨床階段、專註於腫瘤學的生物技術公司，致力於發現和開發KRAS驅動的癌症的專有療法。Silexion的主要候選產品SIL-204B由局部給藥的小干擾RNA或siRNA組成，採用緩釋製劑，作為局部晚期胰腺癌患者的一線治療，與標準護理化療相結合。SIL-204B是繼Silexion的第一代siRNA候選產品SIG12D-LODER（也稱為Loder）的1期和2期臨床試驗之後的第二代siRNA候選產品。儘管未確定最大耐受劑量，但1期臨床試驗同時達到了主要和次要終點。在2期臨床試驗中，雖然沒有達到所有患者的主要終點，但結果显示KRAS G12D/V突變患者的治療組之間存在差異趨勢，Loder組的總體生存期優勢為9.3個月。關於2期臨床試驗中的次要安全性終點，達到了終點。對於次要療效終點，未觀察到統計學上的顯著差異，也沒有足夠的數據進行評估。由於1期和2期試驗的規模較小，它們沒有提供統計學意義。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.0087},{"month":2,"riseRate":0.75,"avgChangeRate":-0.104682},{"month":3,"riseRate":1,"avgChangeRate":0.016028},{"month":4,"riseRate":1,"avgChangeRate":0.008863},{"month":5,"riseRate":0.25,"avgChangeRate":-0.001105},{"month":6,"riseRate":0.5,"avgChangeRate":0.01089},{"month":7,"riseRate":1,"avgChangeRate":0.012186},{"month":8,"riseRate":0.5,"avgChangeRate":-0.219676},{"month":9,"riseRate":0.75,"avgChangeRate":-0.154717},{"month":10,"riseRate":0.5,"avgChangeRate":-0.107747},{"month":11,"riseRate":0.5,"avgChangeRate":0.013201},{"month":12,"riseRate":0.25,"avgChangeRate":-0.069674}],"exchange":"NASDAQ","name":"Silexion Therapeutics Corp","nameEN":"Silexion Therapeutics Corp"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"SLXN\",market:\"US\",,,undefined,":{"directors":[{"name":"Ilan Levin","position":"Chairman of the Board, Director, Secretary and Chief Executive Officer"},{"name":"Craig Marshak","position":"Director"},{"name":"Eric Brachfeld","position":"Director"},{"name":"Michael Basch","position":"Director"},{"name":"Ruth Alon","position":"Director"}],"executives":[{"name":"Ilan Levin","position":"Chairman of the Board, Director, Secretary and Chief Executive Officer"},{"name":"Gil Maman","position":"Chief Financial Officer"},{"name":"Dan Yalon","position":"Advisor"}]}}}